Biologics Outsourcing Global Market - Forecast to 2027

Publishing Date : December, 2018
Report Code : HCPH0110
Price:
Single license $7,200
Site license $9,000
Global license $12,000


The biologics outsourcing global market is expected to grow at double digit CAGR to reach $87.6 billion by 2027. Biologics are therapeutic entities composed of sugars, proteins, or nucleic acids made from natural sources such as human, animal or micro organisms. Biologics can also include live attenuated microorganisms (vaccines), allergenic extracts (allergy shots), human cells and tissues (transplantation), cell therapies and gene therapies. Like small molecule drugs, these drugs are intended for treatment of diseases and medical conditions. However, Biologics bring into picture higher range of specificity in treating a disease condition as the biologic entities like monoclonal antibodies and recombinant proteins target specific areas in the molecular mechanism of disease action.

Although biologics are much costlier than small molecule drugs, these classes of drugs prove to be highly beneficial for the patient and also bring about 40% higher profits to the manufacturers when compared to small molecule drug treatments. Due to the increasing demand for biologics drugs and increased regulatory approvals for these drugs, there is huge demand for biologics manufacture and testing at various levels of clinical studies as well as commercial supply. The Large Biopharma companies are coming up with strategies to cut down on their operational costs and concentrate more on their core competencies by outsourcing this piece of work to contract research organizations (CROs), contract development and manufacturing organizations (CDMOs) and contract manufacturing organizations (CMOs). These organizations bridge the gap between demand and supply and ensure the drug discovery process gets much faster and convenient thus bringing life saving drugs to the market to reach the needy patients.

In 2017, seven out of 10 blockbuster drugs were biologics outnumbering small molecule drugs. Some of the top selling biologics in 2017 includes Humira ($18.4 billion), Rituxan ($9.2 billion), Enbrel ($7.9 billion), and Herceptin ($7.4 billion). The growth of biologics market indirectly indicates the huge demand for services spanning all stages of biologics development starting preclinical stage to commercial manufacturing. The high complexity of biologics development and manufacture requiring huge technical expertise is prompting major biopharma companies turn to outsourcing as a viable option. Various stages of biological development require different types of services as listed below.
Discovery services- Includes lead identification and validation for identifying possible drug candidates targeting specific diseases. The process further involves steps such as target validation, screening preparation, hit generation and lead selection, lead optimization and characterization and finally lead selection.


Preclinical development services- Involves in-vitro and in-vivo studies of the biologic drug candidates before testing them on humans to test the safety, efficacy and biological functionality against the disease target. Preclinical services include cell line engineering, process development, product analytical characterization, cGMP cell banking, cell line characterization, animal model assay development and testing services.
Clinical development- Clinical development includes testing potential drug candidates on humans in phase I, II and II trials. Services at this stage include cGMP grade clinical supply of biologics such as MAb, or recombinant protein, stability testing, fill/finish and regulatory support.

Commercialization- Once the drug has passed all the necessary approvals, the manufacture, marketing and sale of commercial quantities is performed. Outsourcing partners here manufacture the commercial supply for product launch and sale.

  • 1     BIOLOGICS OUTSOURCING GLOBAL MARKET
    • 1.1     INTRODUCTION
    • 1.2     LANDSCAPE OF BIOLOGICS MARKET
    • 1.3     BIOLOGICS GLOBAL MARKET
    • 1.4     TOP DESTINATION FOR BIOLOGICS OUTSOURCING
      • 1.4.1     CHINA BIOLOGICS OUTSOURCING MARKET
      • 1.4.2     CHINA VS INDIA - BIOLOGICS MARKET
      • 1.4.3     REGULATIONS AND GOVERNMENT INITIATIVES
      • 1.4.4     CAPABILITIES AND TECHNOLOGIES
  • 2     MARKET ANALYSIS
    • 2.1     INTRODUCTION
    • 2.2     FACTORS INFLUENCING MARKET
      • 2.2.1     DRIVERS AND OPPORTUNITIES
        • 2.2.1.1     INCREASED INVESTMENT IN R&D BY PHARMACEUTICAL COMPANIES IS INCREASING THE OUTSOURCING
        • 2.2.1.2     ADOPTION OF BIOLOGICAL THERAPIES IN DISEASE MANAGEMENT
        • 2.2.1.3     SUCCESSFUL COLLABORATION AND LOW COST FOR OUTSOURCING
        • 2.2.1.4     INCREASING BIOLOGICS APPROVALS IN THE PAST YEAR
        • 2.2.1.5     INCREASING CHRONIC AND AUTOIMMUNE ILLNESSES
        • 2.2.1.6     INCREASING NUMBER OF BRANDED DRUGS GOING OFF-PATENT CREATES A SCOPE FOR BIOSIMILARS
        • 2.2.1.7     REQUIREMENT OF NOVEL BIOLOGICS THERAPEUTICS FOR RARE DISEASES
        • 2.2.1.8     INCREASING DEMAND FOR ANTIBODY CONJUGATES AND BISPECIFIC ANTIBODIES
        • 2.2.1.9     ADVANCED TECHNOLOGIES FOR SCREENING, CELL LINE ENGINEERING AND BIOPROCESSING
        • 2.2.1.10     PHARMA COMPANIES RESTRICTING THEIR GLOBAL PRESENCE, REDUCING MANPOWER, LACK OF FACILITIES FOR DISCOVERY AND MANUFACTURING OF BIOLOGICS
      • 2.2.2     RESTRAINTS AND THREATS
        • 2.2.2.1     INTENSE COMPLEXITIES IN HANDLING BIOLOGICS
        • 2.2.2.2     REQUIREMENT OF HIGHLY SKILLED TECHNICIANS
        • 2.2.2.3     HIGH COST OF DRUG DEVELOPMENT PROCESS
        • 2.2.2.4     CHALLENGES IN ORAL FORMULATIONS WITH BIOLOGICS
        • 2.2.2.5     STRINGENT REGULATORY FRAMEWORKS
        • 2.2.2.6     HIGH CAPITAL AND TECHNICAL REQUIREMENTS TO OBTAIN GMP CERTIFICATIONS
        • 2.2.2.7     LIMITED IP PROTECTION IN DEVELOPING REGIONS
        • 2.2.2.8     HIGH CHANCES OF END STAGE FAILURE OF DRUG
        • 2.2.2.9     CONFLICT OF INTEREST BETWEEN PHARMACEUTICAL COMPANY AND CRO
  • 3     BIOLOGICS OUTSOURCING GLOBAL MARKET, MARKET ANALYSIS
    • 3.1     INTRODUCTION
    • 3.2     DISCOVERY AND PRE-CLINICAL DEVELOPMENT PROCESS
    • 3.3     BIOLOGICS OUTSOURCING GLOBAL MARKET, BY PRODUCT TYPE
      • 3.3.1     ANTIBODY
        • 3.3.1.1     MONOCLONAL ANTIBODY
        • 3.3.1.2     BISPECIFIC ANTIBODY
        • 3.3.1.3     ANTIBODY DRUG CONJUGATES
        • 3.3.1.4     OTHERS
      • 3.3.2     RECOMBINANT PROTEIN
        • 3.3.2.1     FUSION PROTEINS
        • 3.3.2.2     HORMONES
        • 3.3.2.3     RECOMBINANT ENZYMES
        • 3.3.2.4     OTHERS
      • 3.3.3     VACCINES
      • 3.3.4     OTHERS
        • 3.3.4.1     GENE THERAPY
        • 3.3.4.2     CELL THERAPY
        • 3.3.4.3     OTHERS
    • 3.4     MARKET SHARE ANALYSIS
    • 3.5     COMPANY DEVELOPMENTS
      • 3.5.1     AGREEMENTS, PARTNERSHIPS & COLLABORATIONS
      • 3.5.2     NEW SERVICE LAUNCH
      • 3.5.3     EXPANSION
      • 3.5.4     ACQUISITIONS
      • 3.5.5     OTHER DEVELOPMENTS
    • 3.6     SERVICE COST ANALYSIS
      • 3.6.1     ANTIBODY PRODUCTION SERVICE COSTS
      • 3.6.2     CUSTOM MONOCLONAL ANTIBODY PRODUCTION SERVICE COSTS
      • 3.6.3     CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE COSTS
      • 3.6.4     PROTEIN PRODUCTION SERVICE COSTS
      • 3.6.5     ADDITIONAL ANTIBODY AND PROTEIN SERVICES
      • 3.6.6     GENE EDITTING SERVICES
      • 3.6.7     CAR-T/NK PLATFORM SERVICES
  • 4     BIOLOGICS OUTSOURCING GLOBAL MARKET – ANIMAL MODEL SERVICES
    • 4.1     INTRODUCTION
      • 4.1.1     MARKET DYNAMICS
      • 4.1.2     COMPARISON MATRIX OF ANIMAL MODELS AND APPLICATIONS
      • 4.1.3     SMALL ANIMAL MODELS
      • 4.1.4     LARGE ANIMAL MODELS
    • 4.2     ETHICS AND REGULATIONS
    • 4.3     ALTERNATIVES TO ANIMAL MODELS
    • 4.4     OVERVIEW OF APPLICATIONS OF ANIMAL MODELS
    • 4.5     ANIMAL MODEL SERVICES GLOBAL MARKET, BY MOLECULE
    • 4.6     ANIMAL MODELS SERVICES REGIONAL MARKET
    • 4.7     ANIMAL MODEL SERVICES MARKET, BY SPEICES
    • 4.8     ANIMAL MODEL SERVICES GLOBAL MARKET, BY APPLICATION
    • 4.9     MARKET SHARE ANALYSIS
    • 4.10     COMPETITIVE LANDSCAPE
    • 4.11     COMPANY DEVELOPMENTS
  • 5     BIOLOGICS OUTSOURCING GLOBAL MARKET - BIOMANUFACTURING
    • 5.1     INTRODUCTION
    • 5.2     MARKET DYNAMICS
    • 5.3     IN HOUSE VS CMO CAPACITY
    • 5.4     CONTRACT BIOMANUFACTURING, BY PROCESS
      • 5.4.1     BIOMANUFACTURING BY MAMMALIAN CELL CULTURE
      • 5.4.2     BIOMANUFACTURING BY MICROBIAL CELL CULTURE
      • 5.4.3     BIOMANUFACTURING BY OTHER CELL CULTURE
    • 5.5     CONTRACT BIOMANUFACTURING GLOBAL MARKET, BY END USERS
      • 5.5.1     CONTRACT BIOMANUFACTURING OF DIAGNOSTICS
      • 5.5.2     CONTRACT BIOMANUFACTURING OF RESEARCH REAGENTS
      • 5.5.3     CONTRACT BIOMANUFACTURING OF THERAPEUTICS
    • 5.6     COMPETITIVE LANDSCAPE
      • 5.6.1     CAPACITY COMPARISON
      • 5.6.2     CONTRACT MANUFACTURING GLOBAL MARKET SHARE, BY LEADING
    • 5.7     COMPANY DEVELOPMENTS
      • 5.7.1     MERGER AND ACQUISITION BY CMOS
      • 5.7.2     COLLABORATIONS
      • 5.7.3     CAPACITY EXPANSIONS
  • 6     BIOLOGICS OUTSOURCING GLOBAL MARKET - CELL LINE DEVELOPMENT
    • 6.1     INTRODUCTION
      • 6.1.1     MARKET DYNAMICS
    • 6.2     CELL LINE DEVELOPMENT
      • 6.2.1     CELL LINE CONSTRUCTION
      • 6.2.2     HOST CELL LINE ENGINEERING
      • 6.2.3     EXPRESSION SYSTEM
      • 6.2.4     TRANSIENT GENE EXPRESSION
      • 6.2.5     STABLE CELL LINE DEVELOPMENT
      • 6.2.6     SCREENING
      • 6.2.7     UPSTREAM PROCESS DEVELOPMENT
    • 6.3     HOST CELL LINES
    • 6.4     CELL LINE DEVELOPMENT SERVICES MARKET, BY EXPRESSION SYSTEM
      • 6.4.1     MICROBIAL EXPRESSION SYSTEMS
      • 6.4.2     MAMMALIAN EXPRESSION SYSTEM
      • 6.4.3     OTHERS
    • 6.5     CELL LINE DEVELOPMENT SERVICES, BY CELL TYPE
      • 6.5.1     CHO
      • 6.5.2     MURINE/MOUSE MYELOMA
      • 6.5.3     BABY HAMSTER KIDNEY (BHK) CELLS
      • 6.5.4     HYBRIDOMA
      • 6.5.5     HUMAN EMBRYONIC KIDNEY (HEK) CELLS
      • 6.5.6     HUMAN EMBRYONIC RETINAL CELLS (PER.C6)
      • 6.5.7     OTHERS
    • 6.6     CELL LINE DEVELOPMENT SERVICES, BY APPLICATIONS
      • 6.6.1     RESEARCH
      • 6.6.2     BIOPRODUCTION
      • 6.6.3     DIAGNOSTICS
    • 6.7     KEY DEVELOPMENTS
    • 6.8     MARKET SHARE ANALYSIS
  • 7     COMPANY PROFILES
    • 7.1     ABZENA PLC
      • 7.1.1     OVERVIEW
      • 7.1.2     FINANCIALS
      • 7.1.3     SERVICE PORTFOLIO
      • 7.1.4     KEY DEVELOPMENTS
      • 7.1.5     SWOT ANALYSIS
    • 7.2     ADIMAB LLC.
      • 7.2.1     OVERVIEW
      • 7.2.2     FINANCIALS
      • 7.2.3     SERVICE PORTFOLIO
      • 7.2.4     KEY DEVELOPMENTS
      • 7.2.5     SWOT ANALYSIS
    • 7.3     ALBANY MOLECULAR RESEARCH, INC
      • 7.3.1     OVERVIEW
      • 7.3.2     FINANCIALS
      • 7.3.3     SERVICE PORTFOLIO
      • 7.3.4     KEY DEVELOPMENTS
      • 7.3.5     SWOT ANALYSIS
    • 7.4     BEIJING VITAL STAR BIOTECHNOLOGY CO. LTD.
      • 7.4.1     OVERVIEW
      • 7.4.2     FINANCIALS
      • 7.4.3     SERVICE PORTFOLIO
      • 7.4.4     KEY DEVELOPMENTS
      • 7.4.5     SWOT ANALYSIS
    • 7.5     BOEHRINGER INGELHEIM
      • 7.5.1     OVERVIEW
      • 7.5.2     FINANCIALS
      • 7.5.3     SERVICE PORTFOLIO
      • 7.5.4     KEY DEVELOPMENTS
      • 7.5.5     SWOT ANALYSIS
    • 7.6     CATALENT INC.
      • 7.6.1     OVERVIEW
      • 7.6.2     FINANCIALS
      • 7.6.3     SERVICE PORTFOLIO
      • 7.6.4     KEY DEVELOPMENTS
      • 7.6.5     SWOT ANALYSIS
    • 7.7     CHARLES RIVER LABORATORIES
      • 7.7.1     OVERVIEW
      • 7.7.2     FINANCIALS
      • 7.7.3     SERVICE PORTFOLIO
      • 7.7.4     KEY DEVELOPMENTS
      • 7.7.5     SWOT ANALYSIS
    • 7.8     CROWN BIOSCIENCES (JSR)
      • 7.8.1     OVERVIEW
      • 7.8.2     FINANCIALS
      • 7.8.3     SERVICE PORTFOLIO
      • 7.8.4     KEY DEVELOPMENTS
      • 7.8.5     SWOT ANALYSIS
    • 7.9     GENOWAY
      • 7.9.1     OVERVIEW
      • 7.9.2     FINANCIALS
      • 7.9.3     SERVICE PORTFOLIO
      • 7.9.4     KEY DEVELOPMENTS
      • 7.9.5     SWOT ANALYSIS
    • 7.10     GENSCRIPT BIOTECH CORPORATION
      • 7.10.1     OVERVIEW
      • 7.10.2     FINANCIALS
      • 7.10.3     SERVICE PORTFOLIO
      • 7.10.4     KEY DEVELOPMENTS
      • 7.10.5     SWOT ANALYSIS
    • 7.11     GL BIOCHEM
      • 7.11.1     OVERVIEW
      • 7.11.2     FINANCIALS
      • 7.11.3     SERVICE PORTFOLIO
      • 7.11.4     KEY DEVELOPMENTS
      • 7.11.5     SWOT ANALYSIS
    • 7.12     HORIZON DISCOVERY GROUP, PLC
      • 7.12.1     OVERVIEW
      • 7.12.2     FINANCIALS
      • 7.12.3     SERVICE PORTFOLIO
      • 7.12.4     KEY DEVELOPMENTS
      • 7.12.5     SWOT ANALYSIS
    • 7.13     JACKSON LABORATORY
      • 7.13.1     OVERVIEW
      • 7.13.2     FINANCIALS
      • 7.13.3     SERVICE PORTFOLIO
      • 7.13.4     KEY DEVELOPMENTS
      • 7.13.5     SWOT ANALYSIS
    • 7.14     SAMSUNG BIOLOGICS
      • 7.14.1     OVERVIEW
      • 7.14.2     FINANCIALS
      • 7.14.3     SERVICE PORTFOLIO
      • 7.14.4     KEY DEVELOPMENTS
      • 7.14.5     SWOT ANALYSIS
    • 7.15     JHL BIOTECH INC.
      • 7.15.1     OVERVIEW
      • 7.15.2     FINANCIALS
      • 7.15.3     SERVICE PORTFOLIO
      • 7.15.4     KEY DEVELOPMENTS
      • 7.15.5     SWOT ANALYSIS
    • 7.16     JOINN LABORATORIES CO. LTD
      • 7.16.1     OVERVIEW
      • 7.16.2     FINANCIALS
      • 7.16.3     SERVICE PORTFOLIO
      • 7.16.4     KEY DEVELOPMENTS
      • 7.16.5     SWOT ANALYSIS
    • 7.17     LONZA GROUP
      • 7.17.1     OVERVIEW
      • 7.17.2     FINANCIALS
      • 7.17.3     SERVICE PORTFOLIO
      • 7.17.4     KEY DEVELOPMENTS
      • 7.17.5     SWOT ANALYSIS
    • 7.18     MERCK KGAA
      • 7.18.1     OVERVIEW
      • 7.18.2     FINANCIALS
      • 7.18.3     PRODUCT PORTFOLIO
      • 7.18.4     KEY DEVELOPMENTS
      • 7.18.5     SWOT ANALYSIS
    • 7.19     PATHEON N.V. (THERMOFISHER SCIENTIFIC)
      • 7.19.1     OVERVIEW
      • 7.19.2     FINANCIALS
      • 7.19.3     SERVICE PORTFOLIO
      • 7.19.4     KEY DEVELOPMENTS
      • 7.19.5     SWOT ANALYSIS
    • 7.20     PHARMALEGACY LABORATORIES
      • 7.20.1     OVERVIEW
      • 7.20.2     FINANCIALS
      • 7.20.3     SERVICE PORTFOLIO
      • 7.20.4     KEY DEVELOPMENTS
      • 7.20.5     SWOT ANALYSIS
    • 7.21     PHARMARON
      • 7.21.1     OVERVIEW
      • 7.21.2     FINANCIALS
      • 7.21.3     SERVICE PORTFOLIO
      • 7.21.4     KEY DEVELOPMENTS
      • 7.21.5     SWOT ANALYSIS
    • 7.22     PROSCI INC.
      • 7.22.1     OVERVIEW
      • 7.22.2     FINANCIALS
      • 7.22.3     SERVICE PORTFOLIO
      • 7.22.4     KEY DEVELOPMENTS
      • 7.22.5     SWOT ANALYSIS
    • 7.23     PROTEOGENIX
      • 7.23.1     OVERVIEW
      • 7.23.2     FINANCIALS
      • 7.23.3     SERVICE PORTFOLIO
      • 7.23.4     KEY DEVELOPMENTS
      • 7.23.5     SWOT ANALYSIS
    • 7.24     PSYCHOGENICS, INC
      • 7.24.1     OVERVIEW
      • 7.24.2     FINANCIALS
      • 7.24.3     SERVICE PORTFOLIO
      • 7.24.4     KEY DEVELOPMENTS
      • 7.24.5     SWOT ANALYSIS
    • 7.25     JSR LIFE SCIENCES (SELEXIS SA)
      • 7.25.1     OVERVIEW
      • 7.25.2     FINANCIALS
      • 7.25.3     SERVICE PORTFOLIO
      • 7.25.4     KEY DEVELOPMENTS
      • 7.25.5     SWOT ANALYSIS
    • 7.26     SHANGHAI MEDICILON
      • 7.26.1     OVERVIEW
      • 7.26.2     FINANCIALS
      • 7.26.3     SERVICE PORTFOLIO
      • 7.26.4     KEY DEVELOPMENTS
      • 7.26.5     SWOT ANALYSIS
    • 7.27     SHANGPHARMA CORPORATION /SHANGHAI CHEMPARTNER
      • 7.27.1     OVERVIEW
      • 7.27.2     FINANCIALS
      • 7.27.3     SERVICE PORTFOLIO
      • 7.27.4     KEY DEVELOPMENTS
      • 7.27.5     SWOT ANALYSIS
    • 7.28     SINO BIOLOGICAL
      • 7.28.1     OVERVIEW
      • 7.28.2     FINANCIALS
      • 7.28.3     SERVICE PORTFOLIO
      • 7.28.4     KEY DEVELOPMENTS
      • 7.28.5     SWOT ANALYSIS
    • 7.29     SUNDIA MEDITECH CO., LTD.
      • 7.29.1     OVERVIEW
      • 7.29.2     FINANCIALS
      • 7.29.3     SERVICE PORTFOLIO
      • 7.29.4     KEY DEVELOPMENTS
      • 7.29.5     SWOT ANALYSIS
    • 7.30     SYNGENE INTERNATIONAL
      • 7.30.1     OVERVIEW
      • 7.30.2     FINANCIALS
      • 7.30.3     SERVICE PORTFOLIO
      • 7.30.4     KEY DEVELOPMENTS
      • 7.30.5     SWOT ANALYSIS
    • 7.31     TACONIC BIOSCIENCES
      • 7.31.1     OVERVIEW
      • 7.31.2     FINANCIALS
      • 7.31.3     SERVICE PORTFOLIO
      • 7.31.4     KEY DEVELOPMENTS
      • 7.31.5     SWOT ANALYSIS
    • 7.32     VIVA BIOTECH LTD.
      • 7.32.1     OVERVIEW
      • 7.32.2     FINANCIALS
      • 7.32.3     SERVICE PORTFOLIO
      • 7.32.4     KEY DEVELOPMENTS
      • 7.32.5     SWOT ANALYSIS
    • 7.33     WUXI BIOLOGICS (WUXI APPTEC)
      • 7.33.1     OVERVIEW
      • 7.33.2     FINANCIALS
      • 7.33.3     SERVICE PORTFOLIO
      • 7.33.4     KEY DEVELOPMENTS
      • 7.33.5     SWOT ANALYSIS

      LIST OF TABLES

      • TABLE 1     HIGHLIGHTS OF THE REVISED GUIDELINES
      • TABLE 2     BIOLOGICS OUTSOURCING GLOBAL MARKET REVENUE, BY REGION (2017-2027) ($BN)
      • TABLE 3     BIOLOGICS OUTSOURCING GLOBAL MARKET REVENUE, BY PRODUCT (2017-2027) ($BN)
      • TABLE 4     LIST OF BIOLOGICS APPROVED (2012-2018)
      • TABLE 5     BIOLOGICS OUTSOURCING GLOBAL MARKET REVENUE, BY PHASE (2017-2027) ($BN)
      • TABLE 6     ANTIBODY OUTSOURCING GLOBAL MARKET REVENUE, BY PRODUCT TYPE (2017-2027) ($BN)
      • TABLE 7     OTHERS GLOBAL MARKET REVENUE, BY PRODUCT TYPE (2017-2027) ($BN)
      • TABLE 8     BIOLOGICS OUTSOURCING GLOBAL MARKET REVENUE, BY END USERS (2017-2027) ($BN)
      • TABLE 9     AGREEMENTS, PARTNERSHIP & COLLABOARTION (2017-2018)
      • TABLE 10     NEW SERVICE LAUNCH (2017-2018)
      • TABLE 11     EXPANSION (2017-2018)
      • TABLE 12     ACQUISITIONS (2017-2018)
      • TABLE 13     OTHER DEVELOPMENTS (2017-2018)
      • TABLE 14     SERVICE COMPARISON MATRIX OF THE COMPANY BASED ON BIOLOGICS TYPE
      • TABLE 15     COMPARISON MATRIX OF ANIMAL MODELS AND APPLICATIONS
      • TABLE 16     MAJOR TYPES OF GENETICALLY ENGINEERED AND TRANSPLANTATION ANIMAL MODELS
      • TABLE 17     TYPICAL PRECLINICAL ISSUES OF BIOLOGICS
      • TABLE 18     ANIMAL MODEL SERVICE GLOBAL MARKET, BY MOLECULE ($MN)
      • TABLE 19     ANIMAL MODEL SERVICE GLOBAL MARKET, BY REGION ($MN)
      • TABLE 20     ANIMAL MODEL SERVICE GLOBAL MARKET BY TYPE OF ANIMAL SPECIES ($MN)
      • TABLE 21     ANIMAL MODEL SERVICE GLOBAL MARKET BY APPLICATION ($MN)
      • TABLE 22     ANIMAL MODEL SERVICE COST (DEVELOPMENT OF TRANSGENIC MOUSE)
      • TABLE 23     ANIMAL MODEL SERVICE COST (BASED ON DISEASE MODELS)
      • TABLE 24     ANIMAL MODEL SERVICE COST (IMAGING SERVICE COST)
      • TABLE 25     COMPARISON MATRIX OF ANIMAL MODEL SERVICE COMPANIES AND MODELS IN RESPECTIVE THERAPEUTIC AREAS
      • TABLE 26     COMPARISON MATRIX OF ANIMAL MODEL SERVICE COMPANIES AND MODELS IN RESPECTIVE IMMUNOLOGY/INFLAMMATION THERAPEUTIC AREAS
      • TABLE 27     COMPARISON MATRIX OF ANIMAL MODEL SERVICE COMPANIES AND MODELS IN RESPECTIVE FIBROSIS THERAPEUTIC AREAS
      • TABLE 28     COMPANY DEVELOPMENTS
      • TABLE 29     CAPACITY COMPARISON OF CONTRACT MANUFACTURING ORGANIZATIONS V’S IN-HOUSE CAPACITIES (L)
      • TABLE 30     CONTRACT MANUFACTURING ORGANIZATIONS CAPACITY, BY PROCESS (L)
      • TABLE 31     DRUGS SYNTHESIZED IN MICROBIAL CELL CULTURE
      • TABLE 32     BIOMANUFACTURING OUTSOURCING GLOBAL MARKET BY END USERS 2017-2027 ($BN)
      • TABLE 33     SELECTED FDA APPROVED THERAPEUTIC PEPTIDES AND PROTEINS
      • TABLE 34     BIOMANUFACTURING OUTSOURCING GLOBAL MARKET BY REGION 2017-2027 ($BN)
      • TABLE 35     COMPANY COMPARISON MATRIX, BY MANUFACTURING CAPABILITY
      • TABLE 36     MERGERS AND ACQUISITIONS (2017-2018)
      • TABLE 37     COLLABORATIONS (2017-2018)
      • TABLE 38     CAPACITY EXPANSIONS (2017-2018)
      • TABLE 39     CELL LINE DEVELOPMENT SERVICES MARKET, BY REGION, (2017-2027) ($MN)
      • TABLE 40     APPROVED BIOLOGICS AND CELL LINE TYPE (2012-2018)
      • TABLE 41     NUMBER OF APPROVED BIOLOGICS BY CELL LINE TYPE (2012-2018)
      • TABLE 42     CELL LINE DEVELOPMENT SERVICES MARKET, BY EXPRESSION SYSTEM, (2017-2027) ($MN)
      • TABLE 43     CELL LINE DEVELOPMENT SERVICES MARKET, BY CELL TYPE, (2017-2027) ($MN)
      • TABLE 44     CELL LINE TYPE OF SOME APPROVED BIOLOGICS MODALITIES AND CELL LINE TYPE
      • TABLE 45     CELL LINE DEVELOPMENT SERVICES MARKET, BY APPLICATION, (2017-2027) ($MN)
      • TABLE 46     CELL LINE DEVELOPMENT TECHNOLOGIES
      • TABLE 47     CELL LINE DEVELOPMENT SERVICES COST
      • TABLE 48     KEY DEVELOPMENTS (2017-2018)
      • TABLE 49     COMPARISON MATRIX OF CELL LINE DEVELOPMENT PLAYERS AND SERVICES OFFERED
      • TABLE 50     ABZENA PLC: TOTAL REVENUE AND R&D EXPENSES (2016-2018) ($MN)
      • TABLE 51     ABZENA PLC: TOTAL REVENUE, BY SEGMENT, (2016-2018) ($MN)
      • TABLE 52     ABZENA PLC: TOTAL REVENUE, BY GEOGRAPHY, (2016-2018) ($MN)
      • TABLE 53     BOEHRINGER INGELHEIM: TOTAL REVENUE AND R&D EXPENSES, (2015-2017) ($MN)
      • TABLE 54     BOEHRINGER INGELHEIM: TOTAL REVENUE, BY SEGMENTS, (2015-2017) ($MN)
      • TABLE 55     BOEHRINGER INGELHEIM: TOTAL REVENUE, BY GEOGRAPHY, (2015-2017) ($MN)
      • TABLE 56     CATALENT INC: TOTAL REVENUE AND R&D EXPENSES (2016-2018) ($MN)
      • TABLE 57     CATALENT INC: TOTAL REVENUE, BY SEGMENT, (2016-2018) ($MN)
      • TABLE 58     CHARLES RIVER LABORATORIES: TOTAL REVENUE AND R&D EXPENSES, (2016-2018(Q3)) ($MN)
      • TABLE 59     CHARLES RIVER LABORATORIES: TOTAL REVENUE, BY SEGMENTS, (2016-2018(Q3)) ($MN)
      • TABLE 60     CHARLES RIVER LABORATORIES: TOTAL REVENUE, BY GEOGRAPHY, (2016-2018(Q3)) ($MN)
      • TABLE 61     GENOWAY: TOTAL REVENUE AND R&D EXPENSES (2016-2018(H1)) ($MN)
      • TABLE 62     GENSCRIPT BIOTECH CORPORATION: TOTAL REVENUE AND R&D EXPENSES, (2016-2018(Q3)) ($MN)
      • TABLE 63     GENSCRIPT BIOTECH CORPORATION: TOTAL REVENUE, BY SEGMENTS, (2016-2018(Q3)) ($MN)
      • TABLE 64     GENSCRIPT BIOTECH CORPORATION: TOTAL REVENUE, BY GEOGRAPHY, (2016-2018(Q3)) ($MN)
      • TABLE 65     HORIZON DISCOVERY GROUP: TOTAL REVENUE AND R&D EXPENSES, (2016-2018(H1) ($MN)
      • TABLE 66     HORIZON DISCOVERY GROUP: TOTAL REVENUE, BY SEGMENTS, (2016-2018(H1)) ($MN)
      • TABLE 67     HORIZON DISCOVERY GROUP: TOTAL REVENUE, BY GEOGRAPHY, (2016-2018(H1)) ($MN)
      • TABLE 68     JACKSON LABORATORY: TOTAL REVENUE AND R & D EXPENSES, (2015-2017) ($MN)
      • TABLE 69     SAMSUNG BIOLOGICS CO., LTD: TOTAL REVENUE ($MN)
      • TABLE 70     SAMSUNG BIOLOGICS: TOTAL REVENUE, BY GEOGRAPHY (2016-2018(H1)) ($MN)
      • TABLE 71     JHL BIOTECH: TOTAL REVENUE AND R & D EXPENSES (2015-2017) ($MN)
      • TABLE 72     LONZA GROUP: TOTAL REVENUE & R&D EXPENSES (2016-2018 (H1)) ($MN)
      • TABLE 73     LONZA GROUP: TOTAL REVENUE, BY SEGMENT, (2016-2018(H1)) ($MN)
      • TABLE 74     LONZA GROUP: TOTAL REVENUE, BY GEOGRAPHY (2016-2018(H1)) ($MN)
      • TABLE 75     MERCK KGAA: TOTAL REVENUE AND R&D EXPENSES, (2016-2018(H1)) ($MN)
      • TABLE 76     MERCK KGAA: TOTAL REVENUE, BY SEGMENTS, (2016-2018(H1)) ($MN)
      • TABLE 77     MERCK KGAA: TOTAL REVENUE, BY GEOGRAPHY, (2016-2018 (H1)) ($MN)
      • TABLE 78     PATHEON (THERMOFISHER SCIENTIFIC): TOTAL REVENUE AND R&D EXPENSES (2016-2018 (Q3)) ($MN)
      • TABLE 79     PATHEON (THERMOFISHER SCIENTIFIC): TOTAL REVENUE, BY SEGMENT, (2016-2018(Q3)) ($MN)
      • TABLE 80     SYNGENE INTERNATIONAL: TOTAL REVENUE AND R&D EXPENSES, (2016-2018 (H1)) ($MN)
      • TABLE 81     SYNGENE INTERNATIONAL: TOTAL REVENUE, BY GEOGRAPHY, ((2016-2018 (H1)) ($MN)
      • TABLE 82     WUXI BIOLOGICS: TOTAL REVENUE AND R&D EXPENSES, (2016-2018(H1)) ($MN)

      LIST OF FIGURES

      • FIGURE 1     TOP SELLING DRUGS AND APPROVALS, SMALL MOLECULES V’S BIOLOGICS, 2013-2017
      • FIGURE 2     TOP 30 BIOLOGICS PATENT EXPIRY, 2013-2038 AND RISE OF BIOSIMILARS
      • FIGURE 3     BIOLOGICS REVENUE GENERATION IN NON-TRADITIONAL THERAPIES (2016 VS 2017)
      • FIGURE 4     OUTLOOK OF BIOLOGICS GLOBAL MARKET (2017-2027)
      • FIGURE 5      OUTLOOK OF CHINA BIOLOGICS AND BIOLOGICS OUTSOURCING MARKET (2017-2027)
      • FIGURE 6     CHINA VS INDIA
      • FIGURE 7     MARKET DYNAMICS
      • FIGURE 8     BIOLOGICS OUTSOURCING GLOBAL MARKET REVENUE, BY REGION (2017-2027) ($BN)
      • FIGURE 9     BIOLOGICS OUTSOURCING GLOBAL MARKET SHARE, BY PRODUCT, (2018 V’S 2027) (%)
      • FIGURE 10     DISCOVERY BIOLOGICS OUTSOURCING MARKET SHARE, BY SERVICES 2018 (%)
      • FIGURE 11     DISCOVERY BIOLOGICS OUTSOURCING MARKET, BY SERVICE TYPE, 2018 ($MN)
      • FIGURE 12     BIOLOGICS OUTSOURCING GLOBAL MARKET REVENUE, BY PHASE (2018 V’S 2027) ($BN)
      • FIGURE 13     ANTIBODY OUTSOURCING GLOBAL MARKET REVENUE, BY PRODUCT TYPE, (2018 V’S 2027) ($BN)
      • FIGURE 14     OTHERS GLOBAL MARKET REVENUE, BY PRODUCT TYPE, (2018 V’S 2025) ($BN)
      • FIGURE 15     BIOLOGICS OUTSOURCING GLOBAL MARKET REVENUE, BY END-USERS (2018 V’S 2027) ($BN)
      • FIGURE 16     BIOLOGICS OUTSOURCING GLOBAL MARKET SHARE ANALYSIS, BY MAJOR PLAYERS, 2018
      • FIGURE 17     RECENT DEALS IN BIOLOGICS OUTSOURCING
      • FIGURE 18     GENOME COMPARISON
      • FIGURE 19     DROT: ANIMAL MODELS
      • FIGURE 20     ANIMAL PROFILES
      • FIGURE 21     COMMON ANIMAL MODELS
      • FIGURE 22     ADVANTAGES AND DISADVANTAGES OF RODENT MODELS
      • FIGURE 23     ADVANTAGES AND DISADVANTAGES OF NHP
      • FIGURE 24     PRINCIPLES OF 3RS
      • FIGURE 25     PERCENTAGE OF ANIMALS USED IN DIFFERENT STAGES OF PHARMACEUTICAL DEVELOPMENT
      • FIGURE 26     ANIMAL MODEL SERVICE GLOBAL MARKET, BY MOLECULE ($MN)
      • FIGURE 27     ANIMAL MODEL SERVICE GLOBAL MARKET, BY REGION ($MN)
      • FIGURE 28     ANIMAL MODEL SERVICE GLOBAL MARKET, BY TYPE OF ANIMAL SPECIES ($MN, %)
      • FIGURE 29     ANIMAL MODEL SERVICE GLOBAL MARKET REVENUE AND SHARE, BY APPLICATION ($MN, %(2018))
      • FIGURE 30     ANIMAL MODEL SERVICES GLOBAL MARKET SHARE ANALYSIS, 2018 (%)
      • FIGURE 31     COMPANY DEVELOPMENTS
      • FIGURE 32     MARKET DYNAMICS OF CONTRACT BIOMANUFACTURING GLOBAL MARKET
      • FIGURE 33     GLOBAL MANUFACTURING CAPACITY, CGMP V’S NON-CGMP, INHOUSE V’S CMO, 2017-2027
      • FIGURE 34     CAPACITY UTILIZATION OF CONTRACT MANUFACTURING ORGANIZATIONS, BY STAGE (L)
      • FIGURE 35     CAPACITY COMPARISON OF MAMMALIAN, MICROBIAL AND OTHER CULTURE SYSTEMS (L)
      • FIGURE 36     BIO-MANUFACTURING OUTSOURCING GLOBAL MARKET, BY END USERS ($BN)
      • FIGURE 37     ADC PIPELINE FOR CANCER 2018
      • FIGURE 38     OUTLOOK OF BIOLOGICS CMO GLOBAL MARKET SHARE, BY REGION (%) AND MANUFACTURING IN METRIC TONS, 2018
      • FIGURE 39     CAPACITY COMPOSITION OF TOP 10 CONTRACT MANUFACTURING ORGANIZATIONS (L)
      • FIGURE 40     MARKET SHARE ANALYSIS BY CONTRACT MANUFACTURING MAJOR PLAYERS, 2018
      • FIGURE 41     KEY DEALS (2017-2018)
      • FIGURE 42     MARKET DYNAMICS OF CELL LINE DEVELOPMENT
      • FIGURE 43     CELL LINE DEVELOPMENT SERVICES MARKET, BY REGION, (2018 VS 2027) ($MN)
      • FIGURE 44     NUMBER OF APPROVED BIOLOGICS BY CELL LINE TYPE (2012-2018)
      • FIGURE 45     CELL LINE DEVELOPMENT SERVICES MARKET, BY EXPRESSION SYSTEM, (2018 V’S 2027) ($MN)
      • FIGURE 46     EXPRESSION SYSTEMS OF SOME APPROVED BIOLOGICS
      • FIGURE 47     CELL LINE DEVELOPMENT SERVICES MARKET, BY CELL TYPE, (2018 VS 2027) ($MN)
      • FIGURE 48     CELL LINE TYPE OF SOME APPROVED BIOLOGICS
      • FIGURE 49     CELL LINE TYPE OF SOME APPROVED BIOLOGICS MODALITIES AND CELL LINE TYPE
      • FIGURE 50     CELL LINE DEVELOPMENT SERVICES MARKET, BY APPLICATION, (2018 V’S 2027) ($MN)
      • FIGURE 51     KEY DEVELOPMENTS OF CELL LINE DEVELOPMENT MARKET PLAYERS, 2017-2018
      • FIGURE 52     MARKET SHARE ANALYSIS, BY CELL LINE DEVELOPMENT MAJOR PLAYERS (2018)
      • FIGURE 53     OVERVIEW: ABZENA PLC
      • FIGURE 54     SWOT: ABZENA PLC
      • FIGURE 55     SWOT: ADIMAB LLC
      • FIGURE 56     SWOT: ALBANY MOLECULAR RESEARCH, INC
      • FIGURE 57     SWOT: BEIJING VITAL STAR BIOTECHNOLOGY CO. LTD.
      • FIGURE 58     BOEHRINGER INGELHEIM REVENUE OVERVIEW
      • FIGURE 59     SWOT: BOEHRINGER INGELHEIM
      • FIGURE 60     OVERVIEW: CATALENT INC.
      • FIGURE 61     SWOT: CATALENT INC.
      • FIGURE 62     OVERVIEW: CHARLES RIVER LABORATORIES
      • FIGURE 63     SWOT: CHARLES RIVER LABORATORIES
      • FIGURE 64     SWOT: CROWN BIOSCIENCES
      • FIGURE 65     OVERVIEW: GENOWAY
      • FIGURE 66     SWOT: GENOWAY
      • FIGURE 67     OVERVIEW: GENSCRIPT BIOTECH CORPORATION
      • FIGURE 68     SWOT: GENSCRIPT BIOSCIENCES CORPORATION
      • FIGURE 69     SWOT: GL BIOCHEM
      • FIGURE 70     OVERVIEW: HORIZON DISCOVERY GROUP, PLC
      • FIGURE 71     SWOT: HORIZON DISCOVERY GROUP, PLC
      • FIGURE 72     OVERVIEW: JACKSON LABORATORY
      • FIGURE 73     SWOT: JACKSON LABORATORY
      • FIGURE 74     OVERVIEW: SAMSUNG BIOLOGICS
      • FIGURE 75     SWOT: SAMSUNG BIOLOGICS
      • FIGURE 76     OVERVIEW: JHL BIOTECH
      • FIGURE 77     SWOT: JHL BIOTECH INC.
      • FIGURE 78     SWOT: JOINN LABORATORIES CO. LTD
      • FIGURE 79     OVERVIEW: LONZA GROUP
      • FIGURE 80     SWOT: LONZA GROUP
      • FIGURE 81     OVERVIEW: MERCK KGAA
      • FIGURE 82     SWOT: MERCK KGAA
      • FIGURE 83     OVERVIEW: PATHEON (THERMOFISHER SCIENTIFIC)
      • FIGURE 84     SWOT: THERMO FISHER SCIENTIFIC
      • FIGURE 85     SWOT: PHARMALEGACY
      • FIGURE 86     SWOT: PHARMARON
      • FIGURE 87     SWOT: PROSCI. INC.
      • FIGURE 88     SWOT: PROTEOGENIX
      • FIGURE 89     SWOT: PSYCOGENICS INC
      • FIGURE 90     SWOT: JSR LIFE SCIENCES (SELEXIS SA)
      • FIGURE 91     SWOT: SHANGHAI MEDICILON
      • FIGURE 92     SWOT: SHANGHAI CHEMPARTNER
      • FIGURE 93     SWOT: SINO BIOLOGICAL
      • FIGURE 94     SWOT: SUNDIA MEDITECH COMPANY LTD
      • FIGURE 95     SWOT: SYNGENE INTERNATIONAL
      • FIGURE 96     SWOT: TACONIC BIOSCIENCES
      • FIGURE 97     SWOT: VIVA BIOTECH LTD
      • FIGURE 98     SWOT: WUXI BIOLOGICS